Stock Research for ADRD

ADRD
Current Price

$24.8100


Latest Update: 2018-01-19 16:00:00

High
$ 24.8600
Low
$ 24.8100
Close
$ 24.8600
Volume
200
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ADRD Stock Chart & Research Data

The ADRD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ADRD Due diligence Resources & Stock Charts

The ADRD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRD Detailed Price Forecast - CNN Money CNN View ADRD Detailed Summary - Google Finance
Yahoo View ADRD Detailed Summary - Yahoo! Finance Zacks View ADRD Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ADRD Trends & Analysis - Trade-Ideas Barrons View ADRD Major Holders - Barrons
NASDAQ View ADRD Call Transcripts - NASDAQ Seeking View ADRD Breaking News & Analysis - Seeking Alpha
Spotlight View ADRD Annual Report - CompanySpotlight.com OTC Report View ADRD OTC Short Report - OTCShortReport.com
TradeKing View ADRD Fundamentals - TradeKing Charts View ADRD SEC Filings - Bar Chart
WSJ View Historical Prices for ADRD - The WSJ Morningstar View Performance/Total Return for ADRD - Morningstar
MarketWatch View the Analyst Estimates for ADRD - MarketWatch CNBC View the Earnings History for ADRD - CNBC
StockMarketWatch View the ADRD Earnings - StockMarketWatch MacroAxis View ADRD Buy or Sell Recommendations - MacroAxis
Bullish View the ADRD Bullish Patterns - American Bulls Short Pains View ADRD Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ADRD Stock Mentions - StockTwits PennyStocks View ADRD Stock Mentions - PennyStockTweets
Twitter View ADRD Stock Mentions - Twitter Invest Hub View ADRD Investment Forum News - Investor Hub
Yahoo View ADRD Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRD Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRD - SECform4.com Insider Cow View Insider Transactions for ADRD - Insider Cow
CNBC View ADRD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRD - OTC Markets
Yahoo View Insider Transactions for ADRD - Yahoo! Finance NASDAQ View Institutional Holdings for ADRD - NASDAQ


Stock Charts

FinViz View ADRD Stock Insight & Charts - FinViz.com StockCharts View ADRD Investment Charts - StockCharts.com
BarChart View ADRD Stock Overview & Charts - BarChart Trading View View ADRD User Generated Charts - Trading View


Latest Financial News for ADRD

Teva Pharmaceutical Focusing on Per Product Operating Profits
Posted on Monday January 15, 2018

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.


How AstraZeneca’s Respiratory Products Performed in 3Q17
Posted on Friday December 22, 2017

Pulmicort saw revenues of $242 million during 3Q17, a 9% increase in operating revenues as compared to 3Q16.


How Does Novartis’s Ophthalmology Portfolio Look?
Posted on Wednesday September 20, 2017

In 1H17, Novartis's (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis.


Why New Generic Products Could Boost TEVA’s Revenue Growth
Posted on Friday September 15, 2017

In August 2017, Teva Pharmaceutical (TEVA) launched the generic version of Eli Lilly’s (LLY) Axiron.


BLDRS Developed Markets 100 ADR ETF (ADRD) Rises 0.89% for Jan 17
BZ Weekly - Jan 17, 2018
More important recent BLDRS Developed Markets 100 ADR ETF (NASDAQ:ADRD) news were published by: Forbes.com which released: “Best ETFs: Specialized International” on August 18, 2015, also Nasdaq.

Is Bldrs Developed Markets 100 Adr (NASDAQ:ADRD) a Buy? The Stock Reported ...
KL Daily - Jan 10, 2018
The stock of Bldrs Developed Markets 100 Adr (NASDAQ:ADRD) registered a decrease of 2.07% in short interest. ADRD's total short interest was 18,900 shares in January as published by FINRA.

Best ETFs: Specialized International
Forbes - Aug 18, 2015
The big player in this realm is Vanguard FTSE Emerging Markets (VWO), a China-heavy portfolio that covers most countries not in “developed markets” funds. Conspicuous by its absence is iShares MSCI Emerging Markets (EEM). It fails a 0.4% expense ratio ...

3 ADR ETFs Your Broker Forgot to Mention
NASDAQ - Mar 5, 2013
As an actively managed fund, its 1.25 percent expense ratio is high in the ETF world. Additionally, the fund is small by assets under management and thinly traded.

Enter a stock symbol to view the stock details.